Top

Published in:

Open Access 01-02-2008 | Review

Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system

Authors: Andrea Stephanie Link, Anikó Kuris, Lars Edvinsson

Published in: The Journal of Headache and Pain | Issue 1/2008

Abstract

Primary headaches such as migraine are among the most prevalent neurological disorders, affecting up to one-fifth of the adult population. The scientific work in the last decade has unraveled much of the pathophysiological background of migraine, which is now considered to be a neurovascular disorder. It has been discovered that the trigemino-cerebrovascular system plays a key role in migraine headache pathophysiology by releasing the potent vasodilator calcitonin gene-related peptide (CGRP). This neuropeptide is released in parallel with the pain and its concentration correlates well with the intensity of the headache. The development of drugs of the triptan class has provided relief for the acute attacks but at the cost of, mainly cardiovascular, side effects. Thus, the intention to improve treatment led to the development of small CGRP receptor antagonists such as olcegepant (BIBN4096BS) and MK-0974 that alleviate the acute migraine attack without acute side events. The purpose of this review is to give a short overview of the pathological background of migraine headache and to illustrate the mechanisms behind the actions of triptans and the promising CGRP receptor blockers.

Goadsby PJ (2007) Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13(1):39–44, 17141570, 10.1016/j.molmed.2006.11.005, 1:CAS:528:DC%2BD2sXis1Crtw%3D%3DCrossRefPubMed

Weiller C, May A, Limmroth V et al (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1(7):658–660, 7585147, 10.1038/nm0795-658, 1:CAS:528:DyaK2MXms1Kgsbs%3DCrossRefPubMed

Diener HC, May A (1996) Positron emission tomography studies in acute migraine attacks. In: Sandler M, Ferrari M, Harnett S (eds) Migraine: pharmacology and genetics. Chapman and Hall, London, pp 109–116

Afridi SK, Giffin NJ, Kaube H et al (2005) A positron emission tomographic study in spontaneous migraine. Arch Neurol 62(8):1270–1275, 16087768, 10.1001/archneur.62.8.1270CrossRefPubMed

Edvinsson L, Jansen Olesen I, Kingman TA et al (1995) Modification of vasoconstrictor responses in cerebral blood vessels by lesioning of the trigeminal nerve: possible involvement of CGRP. Cephalalgia 15(5):373–383, 8536296, 10.1046/j.1468-2982.1995.1505373.x, 1:STN:280:DyaK287hsVWhtQ%3D%3DCrossRefPubMed

McCulloch J, Uddman R, Kingman TA et al (1986) Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 83(15):5731–5735, 3488550, 10.1073/pnas.83.15.5731, 1:CAS:528:DyaL28XltV2itr4%3DPubMedCentralCrossRefPubMed

Strong AJ, Fabricius M, Boutelle MG et al (2002) Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke 33(12):2738–2743, 12468763, 10.1161/01.STR.0000043073.69602.09CrossRefPubMed

Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48–56, 8388188, 10.1002/ana.410330109, 1:STN:280:DyaK3s3mtlGqsw%3D%3DCrossRefPubMed

Edvinsson L, Uddman R (2005) Neurobiology in primary headaches. Brain Res Brain Res Rev 48(3):438–456, 15914251, 10.1016/j.brainresrev.2004.09.007CrossRefPubMed

10.

Tajti J, Uddman R, Moller S et al (1999) Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76(2–3):176–183, 10412842, 10.1016/S0165-1838(99)00024-7, 1:CAS:528:DyaK1MXjs1SnsL4%3DCrossRefPubMed

11.

Edvinsson L, Ekman R, Jansen I et al (1987) Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 7(6):720–728, 3500957, 1:CAS:528:DyaL1cXovVeqsg%3D%3DCrossRefPubMed

12.

Gulbenkian S, Uddman R, Edvinsson L (2001) Neuronal messengers in the human cerebral circulation. Peptides 22(6):995–1007, 11390030, 10.1016/S0196-9781(01)00408-9, 1:CAS:528:DC%2BD3MXktVOhurY%3DCrossRefPubMed

13.

Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28(2):183–187, 1699472, 10.1002/ana.410280213, 1:STN:280:DyaK3M%2FisVSktQ%3D%3DCrossRefPubMed

14.

Juhasz G, Zsombok T, Jakab B et al (2005) Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 25(3):179–183, 15689192, 10.1111/j.1468-2982.2005.00836.x, 1:STN:280:DC%2BD2M%2FmtVyqsA%3D%3DCrossRefPubMed

15.

Juhasz G, Zsombok T, Modos EA et al (2003) NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106(3):461–470, 14659530, 10.1016/j.pain.2003.09.008, 1:CAS:528:DC%2BD3sXptlyjs7k%3DCrossRefPubMed

16.

Fanciullacci M, Alessandri M, Figini M et al (1995) Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 60(2):119–123, 7540279, 10.1016/0304-3959(94)00097-X, 1:CAS:528:DyaK2MXkvVSrt7o%3DCrossRefPubMed

17.

Longmore J, Razzaque Z, Shaw D et al (1998) Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol 46(6):577–582, 9862247, 10.1046/j.1365-2125.1998.00821.x, 1:CAS:528:DyaK1MXntFyjPubMedCentralCrossRefPubMed

18.

Nilsson T, Longmore J, Shaw D et al (1999) Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 128(6):1133–1140, 10578124, 10.1038/sj.bjp.0702773, 1:CAS:528:DyaK1MXnvV2hsr8%3DPubMedCentralCrossRefPubMed

19.

Smith D, Hill RG, Edvinsson L et al (2002) An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia 22(6):424–431, 12133041, 10.1046/j.1468-2982.2002.00378.x, 1:STN:280:DC%2BD38visFWquw%3D%3DCrossRefPubMed

20.

Hou M, Kanje M, Longmore J et al (2001) 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 909(1–2):112–120, 11478927, 10.1016/S0006-8993(01)02645-2, 1:CAS:528:DC%2BD3MXls1ejs7Y%3DCrossRefPubMed

21.

Longmore J, Shaw D, Smith D et al (1997) Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 17(8):833–842, 9453271, 10.1046/j.1468-2982.1997.1708833.x, 1:STN:280:DyaK1c7hsVSitA%3D%3DCrossRefPubMed

22.

Martin GR (1997) Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia 17(Suppl 18):4–14, 9399012PubMed

23.

Tfelt-Hansen P (2007) Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 8:287–290

24.

Tfelt-Hansen P, Young WB, Silberstein SD (2006) Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (eds) The headaches, 3rd edn. Lippincott Williams and Wilkins, Philadelphia, pp 505–513

25.

Volans GN (1974) Absorption of effervescent aspirin during migraine. Br Med J 4(5939):265–268, 4425854, 1:STN:280:DyaE2M%2Fjs1yjsQ%3D%3D, 10.1136/bmj.4.5939.265PubMedCentralCrossRefPubMed

26.

Edvinsson L, Uddman E, Wackenfors A et al (2005) Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin Sci (Lond) 109(3):335–342, 1:CAS:528:DC%2BD2MXoslKnsr8%3D, 10.1042/CS20050016CrossRef

27.

Nilsson T, Longmore J, Shaw D et al (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 372(1):49–56, 10374714, 10.1016/S0014-2999(99)00114-4, 1:CAS:528:DyaK1MXjs1ehtbk%3DCrossRefPubMed

28.

MaassenVanDenBrink A, van den Broek RW, de Vries R et al (2000) Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55(10):1524–1530, 11094108, 1:STN:280:DC%2BD3M%2FmvFKmsw%3D%3DCrossRefPubMed

29.

MaassenVanDenBrink A, Reekers M, Bax WA et al (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98(1):25–30, 9665056, 1:STN:280:DyaK1czisl2qsQ%3D%3DCrossRefPubMed

30.

Goadsby PJ (2005) Migraine, allodynia, sensitisation and all of that. Eur Neurol 53(Suppl 1):10–16, 15920332, 10.1159/000085060CrossRefPubMed

31.

Burstein R, Yarnitsky D, Goor-Aryeh I et al (2000) An association between migraine and cutaneous allodynia. Ann Neurol 47(5):614–624, 10805332, 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N, 1:STN:280:DC%2BD3c3mtlSrsA%3D%3DCrossRefPubMed

32.

Bolay H, Reuter U, Dunn AK et al (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8(2):136–142, 11821897, 10.1038/nm0202-136, 1:CAS:528:DC%2BD38Xht1equrc%3DCrossRefPubMed

33.

Lovati C, D’Amico D, Rosa S et al (2007) Allodynia in different forms of migraine. Neurol Sci 28(Suppl 2):S220–221, 17508175, 10.1007/s10072-007-0781-5CrossRefPubMed

34.

Burstein R, Jakubowski M (2004) Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 55(1):27–36, 14705109, 10.1002/ana.10785, 1:CAS:528:DC%2BD2cXhtVOnu7k%3DCrossRefPubMed

35.

Levy D, Jakubowski M, Burstein R (2004) Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A 101(12):4274–4279, 15016917, 10.1073/pnas.0306147101, 1:CAS:528:DC%2BD2cXivFartLY%3DPubMedCentralCrossRefPubMed

36.

Mathew NT, Kailasam J, Seifert T (2004) Clinical recognition of allodynia in migraine. Neurology 63(5):848–852, 15365135CrossRefPubMed

37.

Linde M, Mellberg A, Dahlof C (2006) Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 26(2):113–121, 16426264, 10.1111/j.1468-2982.2005.00999.x, 1:STN:280:DC%2BD28%2FjvFSrsw%3D%3DCrossRefPubMed

38.

Edvinsson L, Jansen I, Kingman TA et al (1990) Cerebrovascular responses to capsaicin in vitro and in situ. Br J Pharmacol 100(2):312–318, 2379036, 1:CAS:528:DyaK3cXkslGltL0%3DPubMedCentralCrossRefPubMed

39.

Jansen-Olesen I, Mortensen A, Edvinsson L (1996) Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16(5):310–316, 8869765, 10.1046/j.1468-2982.1996.1605310.x, 1:STN:280:DyaK2s%2FitlCjtw%3D%3DCrossRefPubMed

40.

Petersen KA, Birk S, Doods H et al (2004) Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 143(6):697–704, 15504760, 10.1038/sj.bjp.0705966, 1:CAS:528:DC%2BD2cXhtVOitrrPPubMedCentralCrossRefPubMed

41.

Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350(11):1104–1110, 15014183, 10.1056/NEJMoa030505, 1:CAS:528:DC%2BD2cXitV2qur0%3DCrossRefPubMed

42.

Ferrari MD, Roon KI, Lipton RB et al (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668–1675, 11728541, 10.1016/S0140-6736(01)06711-3, 1:CAS:528:DC%2BD3MXos1ajsro%3DCrossRefPubMed

43.

Oliver KR, Wainwright A, Edvinsson L et al (2002) Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 22(5):620–629, 11973435, 10.1097/00004647-200205000-00014, 1:CAS:528:DC%2BD38XktlWgsLs%3DCrossRefPubMed

44.

Edvinsson L, Alm R, Shaw D et al (2002) Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 434(1–2):49–53, 11755165, 10.1016/S0014-2999(01)01532-1, 1:CAS:528:DC%2BD38XisVWmCrossRefPubMed

45.

Petersen KA, Nilsson E, Olesen J et al (2005) Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. Cephalalgia 25(6):424–432, 15910566, 10.1111/j.1468-2982.2005.00869.x, 1:STN:280:DC%2BD2M3mvVGisQ%3D%3DCrossRefPubMed

46.

Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142(7):1171–1181, 15237097, 10.1038/sj.bjp.0705807, 1:CAS:528:DC%2BD2cXmvFKqt7Y%3DPubMedCentralCrossRefPubMed

47.

Zhang Z, Winborn CS, Marquez de Prado B et al (2007) Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27(10):2693–2703, 17344407, 10.1523/JNEUROSCI.4542-06.2007, 1:CAS:528:DC%2BD2sXjsVCrtbc%3DCrossRefPubMed

48.

McLatchie LM, Fraser NJ, Main MJ et al (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393(6683):333–339, 9620797, 10.1038/30666, 1:CAS:528:DyaK1cXjsFyjt78%3DCrossRefPubMed

49.

Foord SM, Marshall FH (1999) RAMPs: accessory proteins for seven transmembrane domain receptors. Trends Pharmacol Sci 20(5):184–187, 10354609, 10.1016/S0165-6147(99)01347-4, 1:CAS:528:DyaK1MXksVent7w%3DCrossRefPubMed

50.

Hay DL, Poyner DR, Sexton PM (2006) GPCR modulation by RAMPs. Pharmacol Ther 109(1–2):173–197, 16111761, 10.1016/j.pharmthera.2005.06.015, 1:CAS:528:DC%2BD2MXht12ktbbJCrossRefPubMed

51.

Evans BN, Rosenblatt MI, Mnayer LO et al (2000) CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem 275(40):31438–31443, 10903324, 10.1074/jbc.M005604200, 1:CAS:528:DC%2BD3cXntlCitL4%3DCrossRefPubMed

52.

Goadsby PJ (2005) Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs 65(18):2557–2567, 16392873, 10.2165/00003495-200565180-00002, 1:CAS:528:DC%2BD28Xit1Gqtbg%3DCrossRefPubMed

53.

Rudolf K, Eberlein W, Engel W et al (2005) Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidi nyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem 48(19):5921–5931, 16161996, 10.1021/jm0490641, 1:CAS:528:DC%2BD2MXpt1WhsL8%3DCrossRefPubMed

54.

Doods H, Hallermayer G, Wu D et al (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129(3):420–423, 10711339, 10.1038/sj.bjp.0703110, 1:CAS:528:DC%2BD3cXht1ynsLc%3DPubMedCentralCrossRefPubMed

55.

Gupta S, Mehrotra S, Avezaat CJ et al (2006) Characterisation of CGRP receptors in the human isolated middle meningeal artery. Life Sci 79(3):265–271, 16458930, 10.1016/j.lfs.2006.01.003, 1:CAS:528:DC%2BD28XltFyjsLs%3DCrossRefPubMed

56.

Jansen-Olesen I, Jorgensen L, Engel U et al (2003) In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 481(2–3):207–216, 14642788, 10.1016/j.ejphar.2003.09.021, 1:CAS:528:DC%2BD3sXpt1Cjuro%3DCrossRefPubMed

57.

Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17(5):533–585, 8897024, 10.1210/er.17.5.533, 1:CAS:528:DyaK28XmvF2hs7Y%3DCrossRefPubMed

58.

Saetrum Opgaard O, Hasbak P, de Vries R et al (2000) Positive inotropy mediated via CGRP receptors in isolated human myocardial trabeculae. Eur J Pharmacol 397(2–3):373–382, 10844137, 10.1016/S0014-2999(00)00233-8, 1:CAS:528:DC%2BD3cXjslyjtLo%3DCrossRefPubMed

59.

Wallengren J, Ekman R, Sundler F (1987) Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical and immunochemical study on normal skin and blister fluid from inflamed skin. Acta Derm Venereol 67(3):185–192, 2442929, 1:CAS:528:DyaL2sXlslelurw%3DPubMed

60.

Iovino M, Feifel U, Yong CL et al (2004) Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 24(8):645–656, 15265053, 10.1111/j.1468-2982.2004.00726.x, 1:STN:280:DC%2BD2czmt1SntQ%3D%3DCrossRefPubMed

61.

Edvinsson L (2002) Calcitonin gene-related peptide (CGRP) in cerebrovascular disease. ScientificWorldJournal 2:1484–1490, 12805934, 10.1100/tsw.2002.806CrossRefPubMed

62.

Petersen KA, Birk S, Lassen LH et al (2005) The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 25(2):139–147, 15658951, 10.1111/j.1468-2982.2004.00830.x, 1:STN:280:DC%2BD2M%2Fjt1Kktw%3D%3DCrossRefPubMed

63.

Gupta S, Akerman S, van den Maagdenberg AM et al (2006) Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine. Cephalalgia 26(11):1294–1303, 17059436, 10.1111/j.1468-2982.2006.01219.x, 1:STN:280:DC%2BD28nis1antA%3D%3DCrossRefPubMed

64.

Edvinsson L (2004) Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 24(8):611–622, 15265049, 10.1111/j.1468-2982.2003.00719.x, 1:STN:280:DC%2BD2czmt1SnsQ%3D%3DCrossRefPubMed

65.

Petersen KA, Lassen LH, Birk S et al (2005) BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77(3):202–213, 15735614, 10.1016/j.clpt.2004.10.001, 1:CAS:528:DC%2BD2MXhsVyrs7Y%3DCrossRefPubMed

66.

Edvinsson L, Nilsson E, Jansen-Olesen I (2007) Inhibitory effect of BIBN4096BS, CGRP(8–37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 150(5):633–640, 17245362, 10.1038/sj.bjp.0707134, 1:CAS:528:DC%2BD2sXisVeisL8%3DPubMedCentralCrossRefPubMed

67.

Paone DV, Shaw AW, Nguyen DN et al (2007) Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 50(23):5564–5567, 17929795, 10.1021/jm070668p, 1:CAS:528:DC%2BD2sXhtFCisbfOCrossRefPubMed

68.

Hershey JC, Corcoran HA, Baskin EP et al (2005) Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul Pept 127(1–3):71–77, 15680472, 10.1016/j.regpep.2004.10.010, 1:CAS:528:DC%2BD2MXosVGntw%3D%3DCrossRefPubMed

69.

Ho TW, Mannix LK, Fan X et al (2007) Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology (Epub ahead of print)

Title: Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system
Authors: Andrea Stephanie Link
Anikó Kuris
Lars Edvinsson
Publication date: 01-02-2008
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2008
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1007/s10194-008-0011-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Thoughts on the past year of Journal of Headache and Pain

Medically treated deep neck abscess presenting with occipital headache and meningism

More lessons for the treatment of chronic daily headache

Alcohol and migraine: trigger factor, consumption, mechanisms. A review

Pharmacogenomics and migraine: possible implications

Erratum to: Thoughts on the past year of Journal of Headache and Pain